Le Lézard
Classified in: Health
Subjects: NPT, LEG, AVO

501 Health Care Practices Across the Country Urge Congress to Act to Protect Value-Based Care Incentives


WASHINGTON, Dec. 2, 2020 /PRNewswire/ -- Next Generation ACO Coalition members joined hundreds of health care practices across the US today in a letter calling on Congressional leaders to act to ensure access to strong financial incentives for clinicians participating in two-sided risk models that deliver high quality, coordinated, cost-effective care.

Congress enacted legislation ? the bipartisan Medicare Access and CHIP Reauthorization Act (MACRA) ? established an incentive payment for providers who participate in Advanced Alternative Payment Models (APMs). The law included a five percent Medicare bonus intended to accelerate the transformation away from fee-for-service, volume-based reimbursement. This funding helps clinicians continue to build on the success of these models, driving further innovation that benefits patients. To qualify for the bonus, Advanced APMs must achieve certain revenue or patient count thresholds to demonstrate sufficient shifts to risk-bearing models.

Both the revenue and patient participation thresholds for the advanced APM bonus are scheduled to significantly increase in 2021. To currently qualify for the five percent bonus clinicians must have 50 percent of payments or 35 percent of patients in an advanced APM. In 2021, the thresholds jump to 75 percent of payments or 50 percent of patients. These dramatic increases will cause many clinicians, including those participating in the highest levels of financial risk available in the Medicare program, to lose the opportunity to qualify for a bonus payment.

"Next Generation ACOs and their clinicians are participating in the highest level of risk bearing model currently available in traditional Medicare," said Mara McDermott, Next Generation ACO Coalition's Executive Director. "For them to miss out on their bonus opportunity would go against the intent of MACRA and its value-based care incentives."

Today, 501 practices, including Next Generation accountable care organizations (ACOs), are calling on Leadership in the House and Senate to freeze the MACRA APM thresholds at the 2020 levels for the next two performance years. "This freeze will give us the flexibility and financial security we need to continue to innovate and improve population health for our patients, as well as to continue to drive forward models that create a fiscally health future for the Medicare program" the letter states.

The increased threshold is set to take effect January 1, 2021.

About Next Generation ACO Coalition
The Next Generation ACO Coalition represents ACOs across the country who are working to improve care and lower costs through risk-bearing alternative payment models. For more information, visit our website.

SOURCE Next Generation ACO Coalition


These press releases may also interest you

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...



News published on and distributed by: